Recent Updates
Recently added Catalysts

Izalontamab brengitecan

Phase 1

Lung Cancer | Small molecule | Oncology |Bristol-Myers Squibb Company|Last Updated: Aug 18, 2026

Target and mechanism

ModalitySmall molecule

Also known as BMS-986507

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment416

FDA Designations

No designations recorded

Clinical trial landscape

Izalontamab brengitecan · 1 trial · 2 indications

Phase 1 1
NCT06618287A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsLung Cancer
RECRUITING416 Analytics
PHASE1RECRUITING
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Lung Cancer
NCT06618287416
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of participants with adverse events (AEs)
Up to 3 years
Number of participants with serious adverse events (SAEs)
Up to 3 years
Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) critera
Up to 3 years
Number of participants with AEs leading to discontinuation
Up to 3 years
Number of participants with AEs leading to death
Up to 3 years
Number of DLTs that occur during the DLT evaluation period
Up to 3 weeks

Secondary Endpoints

Maximum observed serum concentration (Cmax)
Up to 3 years
Time of maximum observed concentration (Tmax)
Up to 3 years
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Up to 3 years
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Group AEXPERIMENTAL -
Group BEXPERIMENTAL -
Group CEXPERIMENTAL -
Group DEXPERIMENTAL -
Group EEXPERIMENTAL -

Interventions

NameTypeDescription
BMS-986507DRUGSpecified dose on specified days
OsimertinibDRUGSpecified dose on specified days
PembrolizumabDRUGSpecified dose on specified days
NivolumabDRUGSpecified dose on specified days
PumitamigDRUGSpecified dose on specified days
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites66

Inclusion Criteria * Participants must have at least one measurable lesion per response evaluation criteria in solid tumors. * Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Participants must have a life expectancy of at least 3 months at the tim...

Countries:United StatesAustraliaCanadaChileFranceItalyNetherlandsSpainTaiwanUnited Kingdom
Unlock Eligibility Criteria

Competitive Landscape -Lung Cancer 280 trials

Top 20 of 76 competitors

CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK10PHASE3Pembrolizumab, Olaparib, Etoposide/m^2
Gilead Sciences, Inc.GILD5PHASE3Sacituzumab Govitecan, Topotecan, Amrubicin, Lurbinectedin
Amgen Inc.AMGN14PHASE3Tarlatamab, Durvalumab, Carboplatin, Etoposide
AstraZeneca PLCAZN31PHASE3Durvalumab
BioNTech SE Sponsored ADRBNTX6PHASE3PM8002, Paclitaxel, Topotecan
Pfizer Inc.PFE13PHASE3PF-08634404, Pembrolizumab, Chemotherapy Regimen 1
AbbVie, Inc.ABBV4PHASE3ABBV-706, Topotecan, Lurbinectedin, Amrubicin
Bristol-Myers Squibb CompanyBMY14PHASE3MRTX849, Docetaxel
ArriVent BioPharma, Inc.AVBP6PHASE3furmonertinib, daily, platinum-based chemotherapy
Eli Lilly and CompanyLLY3PHASE3Ramucirumab, Erlotinib, Gefitinib, Osimertinib
Jazz Pharmaceuticals Public Limited CompanyJAZZ3PHASE3Atezolizumab, Lurbinectedin, Carboplatin, Etoposide
Revolution Medicines, Inc.RVMD2PHASE3daraxonrasib, docetaxel
Summit Therapeutics IncSMMT1PHASE3AK112
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK1PHASE3TAK-788, Pemetrexed, Cisplatin, Carboplatin
Immutep Ltd Sponsored ADRIMMP2PHASE3eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin, pemetrexed, pembrolizumab
Regeneron Pharmaceuticals, Inc.REGN5PHASE2BNT116, Cemiplimab
GSK plc Sponsored ADRGSK1PHASE3Ris-Rez, Topotecan
Zai Lab Ltd. Sponsored ADRZLAB2PHASE3ZL-1310
NovoCure Ltd.NVCR1PHASE3Pembrolizumab, Platinum based chemotherapy
ImmunityBio IncIBRX2PHASE3N-803, Tislelizumab, Docetaxel, Prior failed checkpoint inhibitor
Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

LOWAug 19, 2026NCT06618287lastUpdatePostDate: changed
LOWAug 19, 2026NCT06618287lastUpdatePostDate: changed
LOWAug 19, 2026NCT06618287lastUpdatePostDate: changed
LOWJul 24, 2026NCT06618287lastUpdatePostDate: changed
LOWJul 24, 2026NCT06618287lastUpdatePostDate: changed
LOWJul 2, 2026NCT06618287lastUpdatePostDate: changed
LOWJul 2, 2026NCT06618287lastUpdatePostDate: changed
LOWJul 2, 2026NCT06618287lastUpdatePostDate: changed
LOWJul 2, 2026NCT06618287lastUpdatePostDate: changed